Company Filing History:
3 out of 5,089 
3 out of 1,744 
3 out of 23 
Years Active: 2022-2024
Title: Innovator in Gene Therapy: The Contributions of Mathieu Mevel
Introduction: Mathieu Mevel is a distinguished inventor based in Nantes, France, recognized for his significant contributions to the field of gene therapy. With a portfolio of three patents, he has been instrumental in advancing the understanding and application of recombinant Adeno-Associated Virus (rAAV) technology for gene delivery.
Latest Patents: Among his most recent innovations is the patent for rAAV with chemically modified capsid. This invention details a recombinant AAV vector particle that incorporates at least one primary amino group in the capsid proteins, which is chemically coupled with a ligand through a bond that includes a —CSNH— bond and an optionally substituted aromatic moiety. This advancement is pivotal for enhancing gene delivery efficacy through viral vectors and is particularly focused on targeted gene delivery to specific cells, tissues, and organs. Furthermore, the method he developed allows for the chemical coupling of the AAV vector particle with various ligands, broadening the potential therapeutic applications of rAAV in medical contexts.
Career Highlights: Mathieu Mevel's career has been marked by his tenure at prominent research organizations. He has worked at the Centre National de la Recherche Scientifique (CNRS) and the Institut National de la Santé et de la Recherche Médicale (INSERM), where his work has significantly supported advancements in medical research and therapeutic development.
Collaborations: Throughout his career, Mathieu has collaborated with notable colleagues in the field, including David Deniaud and Eduard Ayuso. These partnerships have enriched his research endeavors, allowing for a multidisciplinary approach to solving complex challenges in gene therapy.
Conclusion: Mathieu Mevel has made substantial strides in the realm of gene therapy, particularly through his patented inventions that enhance AAV technology. His work reflects a commitment to advancing medical science and improving therapeutic outcomes, marking him as a key figure in innovative research and development within this critical field.